Cancer Center Clínica Universidad de Navarra (CCUN)

Centro clínico de la Universidad de Navarra

Foto de Cancer Center Clínica Universidad de Navarra (CCUN)

Foto de Shanghai Changzheng Hospital

Shanghai Changzheng Hospital

Shangai, China

Publicaciones en colaboración con investigadores/as de Shanghai Changzheng Hospital (3)

2024

Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology

2016

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial
The Lancet Haematology, Vol. 3, Núm. 11, pp. e506-e515

2011

Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: Analysis of the VISTA trial
British Journal of Haematology, Vol. 153, Núm. 2, pp. 212-221